Screening and Management of Hyperuricemia in Patients with Chronic Medical Diseases in Assiut University Hospital

NCT ID: NCT06586229

Last Updated: 2024-09-19

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 61 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-10-01
• Study Completion Date: 2025-11-01

Brief Summary

In this study, we aimed to evaluate patients with chronic medical diseases in Assiut university hospitals for -Detection of asymptomatic hyperuricemia .

• Early identification of associated comorbidities .
• Management of indicated hyperurecimia .

Detailed Description

Hyperuricemia is classically defined as a serum uric acid (SUA) of more than 7.0 mg/dL in men or more than 6.0 mg/dL in women . Asymptomatic hyperuricemia is a condition, where patients have elevated levels of SUA, yet do not exhibit symptoms or signs of monosodium urate crystal deposition, such as gout attacks, urolithiasis, or uric acid nephropathy . SUA can be elevated 10 to 15 years before clinical manifestations of gout . Up to 21% of the general population and 25% of hospitalized patients are estimated to have asymptomatic hyperuricemia .

Uric acid excretion mostly occurs via the kidneys, so decreased glomerular filtration rates in chronic kidney (CKD) patients contribute to the population increase in hyperuricemia. Conversely, studies suggest that hyperuricemia may contribute to CKD , raising the possibility that urate-lowering therapies (ULTs) could be useful in slowing CKD progression . There was no independent association between hyperuricemia and systemic arterial hypertension. Also, hyperuricemia has been reported as an independent risk factor for both coronary artery disease, congestive heart failure and diabetes mellitus.

So efforts should be made to recognize individuals at risk of hyperuricemia by evaluating dietary habits, family history, and lifestyle factors, and regularly monitor SUA levels. As well as, management strategies, including lifestyle modifications, pharmacotherapy, and dietary interventions, to effectively control SUA and reduce the risk of associated complications.

Conditions

Hyperuricemia

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: CROSS_SECTIONAL

Eligibility Criteria

Inclusion Criteria

• Patients 18 years of age or older who were diagnosed with chronic medical diseases as diabetes mellitus , hypertension , obesity , metabolic syndrome , chronic kidney disease and cardiovascular disease (ischemic cardiomyopathy, heart failure ,coronary arteries disease) .

Exclusion Criteria

• patients under the age of 18.
• patients kown to have gouty arthritis
• patients with acute kidney disease .
• patients receiving thiazide diuretics.
• patients with tumour lysis syndrome .

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assiut University

OTHER

Sponsor Role: lead

Responsible Party

Huda Abdelkader

principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Huda Abdelkader Khalafallah

Role: PRINCIPAL_INVESTIGATOR

Assiut University

Mohammed Abbas Sobh

Role: STUDY_DIRECTOR

Assiut University

Ayat Salah Ahmed

Role: STUDY_DIRECTOR

Assiut University

Central Contacts

Huda A Khalafallah

Role: CONTACT

hudaabdelkader.1998@gmail.com

+2001156854695

Other Identifiers

screening of hyperuricmia

Identifier Type: -

Identifier Source: org_study_id